79 results about "Compulsive disorders" patented technology

This invention provides compounds of the formula: 1 wherein R.sub.1 and R.sub.2 are each, independently, H, alkyl, cycloalkyl, --CH.sub.2-cycloalkyl, alkoxy, halogen, fluorinated alkyl, --CN, --NH--SO.sub.2-alkyl, --SO.sub.2--NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, fluorinated alkoxy, acyl, or phenoyl or thiophenoyl; R.sub.3 and R.sub.4 are each, independently, H, alkyl or cycloalkyl; R.sub.5 is H or alkyl; R.sub.6 is H or; and the dashed line indicates an optional double bond; or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions and methods utilizing these compounds for the treatment or prevention of disorders including obsessive-compulsive disorder, depression, anxiety, generalized anxiety disorder, schizophrenia, migraine, sleep disorders, eating disorders, obesity, epilepsy, and spinal cord injury.

This invention is directed to pharmaceutical compositions and methods for treating a disorder or condition selected from the group consisting of depression, anxiety disorders, phobias, avoidant personality disorder, eating disorders, chemical dependencies, Parkinson's diseases, obsessive-compulsive disorder, negative symptoms of schizophrenia, cognitive dysfunction related to schizophrenia, premenstrual syndrome, stress-induced incontinence, headache, neuropathic pain, chronic pain, urinary incontinence, post-traumatic stress disorder, chronic stress, acute stress, fibromyalgia, depression comorbid with fibromyalgia, obesity, migraine and a combination thereof in a mammal. The methods in one embodiment comprise administering to a mammal in need of treatment for the disorder or condition: (i) at least one serotonin reuptake inhibitor or pharmaceutically acceptable salt thereof; (ii) at least one norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof, wherein the norepinephrine reuptake inhibitor is selected from the group consisting of Structure II, Structure III, and Structure IV as defined in the specification; and (iii) a pharmaceutically acceptable carrier. The pharmaceutical compositions and methods of the invention are also useful for preventing a relapse associated with one of the foregoing disorders or conditions, and for treating a symptom associated with one of the foregoing disorders or conditions, wherein the symptom is selected from the group consisting of cognitive dysfunctions and somatic complaints.

Unsaturated nitrogen heterocyclic compounds of formula (I):as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.

The present invention provides compounds of formula I which are capable of inhibition of the activation of hNav1.1 or hNav1.6 sodium channels in neurons. Pharmaceutical compositions comprising these compounds are also provided. Methods for prevention and treatment of neurological disorders, including, for example, seizures and seizure disorders, including Lennox-Gastaut Syndrome, Dravet syndrome, epileptic encephalopathies, autism, Familial hemiplegic migraine (FHM), anxiety disorders, including Post-traumatic stress disorder (PTSD), panic disorder and obsessive-compulsive disorder, neuropathic pain, and Rett syndrome by administration of these compounds are also provided.

This invention relates to an effective dietary intervention plan. In one aspect all food is withheld for a period of at least 5 days, except for tropical root crops. In another aspect the invention relates to the treatment of various symptoms, conditions or diseases such as Diarrhea, constipation, congestion, eczema, asthma, fatigue, muscle weakness, tension, and spasms, irritable bowel syndrome, swelling, anxiety, multiple chemical sensitivities, moderate to extensive and moderate to severe symptoms due to food allergies, sensitivities, and intolerances, bloating, pain, headaches, leaky gut, hyperactivity, sleeping difficulties, severe underweight, eating disorders, obsessive, compulsive disorders, panic attacks, sensory sensitivities, Alzheimer's disease, acid reflux, irritability, delayed motor skills, delayed social skills, autism, PDD, infantile spasms, seizures by withholding from the patient for a period of at least 5 days all food except for concentrated forms of concentrated tropical root crops. Preferably the patient is also removed from external environmental sources of allergens. After the initial withholding period new foods may be introduced according to a particular selection and schedule. In another aspect of the invention the subject undergoes an effective dietary intervention plan in which at least five (5) tropical root crops are selected, each eaten on a successive day, along with selected other meat, vegetables, and oils that the subject has never eaten before, eating a different selection of meat, vegetables, and oils each from different food families each day, with no food or food family being repeated for at least 5 days. In another aspect the invention relates to the treatment of various symptoms, conditions or diseases such as Diarrhea, constipation, congestion, eczema, asthma, fatigue, muscle weakness, tension, and spasms, irritable bowel syndrome, swelling, anxiety, multiple chemical sensitivities, moderate to extensive and moderate to severe symptoms due to food allergies, sensitivities, and intolerances, bloating, pain, headaches, leaky gut, hyperactivity, sleeping difficulties, severe underweight, eating disorders, obsessive, compulsive disorders, panic attacks, sensory sensitivities, Alzheimer's disease, acid reflux, irritability, delayed motor skills, delayed social skills, autism, PDD, infantile spasms, seizures by withholding from the patient for a period of at least 5 days all food except for concentrated forms of concentrated tropical root crops. Preferably the patient is also removed from external environmental sources of allergens. After the initial withholding period new foods may be introduced according to a particular selection and schedule. In another aspect of the invention the subject undergoes an effective dietary intervention plan in which at least seven (7) tropical root crops are selected, each eaten on a successive day, along with selected other meat, vegetables, and oils that the subject has never eaten before, eating a different selection of meat, vegetables, and oils each from different food families each day, with no food or food family being repeated for at least 7 days. In another aspect the invention relates to the treatment of various symptoms, conditions or diseases such as Diarrhea, constipation, congestion, eczema, asthma, fatigue, muscle weakness, tension, and spasms, irritable bowel syndrome, swelling, anxiety, multiple chemical sensitivities, moderate to extensive and moderate to severe symptoms due to food allergies, sensitivities, and intolerances, bloating, pain, headaches, leaky gut, hyperactivity, sleeping difficulties, severe underweight, eating disorders, obsessive, compulsive disorders, panic attacks, sensory sensitivities, Alzheimer's disease, acid reflux, irritability, delayed motor skills, delayed social skills, autism, PDD, infantile spasms, seizures by withholding from the patient for a period of at least 5 days all food except for concentrated forms of concentrated tropical root crops. Preferably the patient is also remo

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, childhood enuresis, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.

The invention provides fluvoxamine maleate sustained release tablets. The fluvoxamine maleate sustained release tablets are prepared from 50 parts of fluvoxamine maleate, 50-150 parts of sustained release skeleton material and 5-25 parts of lubricating agent by weight. A preparation method of the fluvoxamine maleate sustained release tablets comprises the steps of material preparing, blending, granulating, blending, tabletting and aluminium-plastic packaging. The fluvoxamine maleate sustained release tablets and the preparation method have the beneficial effects that the fluvoxamine maleate sustained release tablets are used for treating depression and associated symptoms as well as symptoms of obsessive-compulsive disorder and have definite curative effects and small side effects; the novel sustained release preparations are adopted; sustained release refers to reducing the medicine release rates of medicines from the dosage forms and reducing the absorption rates of the medicines into bodies, thus achieving more stable treatment effects; compared with oral liquids, the fluvoxamine maleate sustained release tablets have the advantages of good medicine stability, convenience in packaging, transportation and storage, and the like; the preparation method is simple and practicable and is suitable for industrial production.

Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.

Unsaturated nitrogen heterocyclic compounds of formula (I):as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

The invention belongs to the technical fields of medical equipment and Internet-of-Things intelligent electronics, particularly relates to the healthcare field of forgetful old men / patients with an obsessive-compulsive disorder (OCD), and discloses an intelligent voice prompting device used by a forgetful old man or a patient with the OCD. The intelligent voice prompting device comprises a shell, a power switch, a microphone, a loudspeaker, a talking switch, an intelligent voice circuit and a battery. When a user, namely the forgetful old man or the patient with the OCD, intends to do a certain thing, the user talks to the intelligent voice prompting device about the certain thing the user wants to do, then the intelligent voice prompting device can send out voice prompts to tell the user about the time when the certain thing is done last time and how long from the time when the certain thing is done to the present, and suggest the user to do or not to do the certain thing, the user tells a decision about whether the certain thing is to be done or not, and the intelligent voice prompting device records the decision which is made by the user this time for next use. The intelligent voice prompting device can store different incident modules such as a hand washing module, a going-to-toilet module, a door closing module and a cleaning module. The intelligent voice prompting device can help the user, namely the forgetful old man or the patient with the OCD, to avoid the embarrassment that the user keeps on doing the same thing repeatedly due to the fact that the user forgets or does not trust the thing which is just done by the user, and therefore the living quality of the user is improved.

Provided is a human RE2-L protein, as well as the encoding nucleic acid, methods for screening for agents capable of modulating RE2-L related activity and treating RE2-L-mediated conditions. Further provided are animal models useful for screening agents capable of ameliorating or reducing anxiety related disorders and obsessive-compulsive disorders.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive- compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.

A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.

One aspect of the invention provides a method of treating a subject diagnosed with one or more mental disorders selected from the group consisting of: anxiety disorders, mood disorders, trauma-associated disorders, psychotic disorders, and obsessive-compulsive disorder and related disorders. The method includes: performing near-infrared spectroscopy (NIRS) imaging of one or more regions of interest in the subject's brain; presenting a representation of the NIRS imaging to the subject; and while continuing to perform the performing and presenting steps: presenting a stimulus of anxiety or other symptomatology to the subject; instructing the subject to increase activity in the one or more regions of interest; and instructing the subject to decrease activity in the one or more regions of interest.

The invention relates to the technical field of medicine, in particular to a use of the Amuc1100 protein. The research shows that the Amuc1100 protein or a host expressing the Amuc1100 protein has theeffect of improving the emotion memory, including promoting the regression of the negative emotion memory and / or enhancing the positive emotion memory. The Amuc1100 protein can be applied to the preparation of drugs for addiction withdrawal, or can be applied to the preparation of drugs for treating at least one of anxiety disorder, obsessive-compulsive disorder, autism, dementia and schizophrenia.

The invention relates to a prediction system for predicting obsessive-compulsive disorder treatment effect of tDCS based on EEG, and the system comprises: a data collection and processing module which is used for collecting resting-state EEG data of a subject; a data preprocessing module which is used for carrying out filtering processing on the collected EEG data and removing signals containing artifacts; a data spectrum analysis processing module which is used for converting the EEG time domain signals into frequency domain signals by using fast Fourier transform, and performing division processing according to different frequency bands; and a curative effect prediction processing module which is used for judging the curative effect prediction condition of tDCS treatment according to the comparative relationship between the characteristic curve of the subject and the optimal critical point. The invention further relates to a corresponding method and device, a processor and a storage medium thereof. By adopting the system, the method, the device, the processor and the storage medium, the curative effect prediction method for treating obsessive-compulsive disorder based on the EEG tDCS is used for the first time, the algorithm accuracy is high, and the key problem that the treatment method is difficult to select in the clinical diagnosis and treatment process can be solved.

The present disclosure relates to the transdermal administration of psychedelics, such as psilocybin, psilocin, lysergic acid diethylamine (LSD), and / or ibogaine, and derivatives of these compounds, for the treatment and / or prevention and / or control of severe depression (treatment resistant), major depressive disorder, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, opioid addiction, anxiety (stress), adult ADHD, cluster headaches, and cancer related or other end-of-life psychological distress.

The invention discloses beta-carboline derivatives with structural characteristics shown in a formula (I), and also discloses pharmaceutically acceptable salts of the beta-carboline derivatives, a preparation method of the beta-carboline derivatives and application of the beta-carboline derivatives as selective monoamine oxidase B inhibitors. The compounds of the invention are useful for the treatment of neuropsychiatric and degenerative diseases modulated by selective monoamine oxidase B inhibitors, including Parkinson's disease, Alzheimer's disease, obsessive-compulsive disorder, depression, schizophrenia, anorexia nervosa and migraine.

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compoundsuseful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.

The invention provides a novel application of a Pinghuwanxing sesquiterpene compound, namely Isonardosinone or kanshone E, of nardostachys chinensis batal.; the Pinghuwanxing sesquiterpene compound of the nardostachys chinensis batal. is obtained from rhizome of the nardostachys chinensis batal., which belongs to valerianaceae nardostachys plants, by separating and purifying; the sesquiterpene compound has a 5-serotonin transporter (SERT) enhanced activity; the sesquiterpene compound, as a rare SERT activity promoter, is applicable to preparing medicines for treating such neuropsychiatric diseases as depression, anxiety disorder, schizophrenia, obsessive-compulsive disorder, neurodegenerative disease, drug addiction and the like as well as medicines for treating such digestive system dysfunction diseases as slow transit constipation, irritable bowel syndrome, functional abdominal distention and the like; and the sesquiterpene compound has an important medicine development value.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.

Provided are compositions for use in treating a patient suffering from a mental disorder in particular major depressive disorder, persistent depressive disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse. Further provided are dosing regimens for treating these disorders.

The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example an addiction or compulsive disorder.

The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.